APA 6th Edition Rahelić, D., Altabas, V., Bakula, M., Balić, S., Balint, I., Bergman Marković, B., ... Krznarić, Ž. (2016). HRVATSKE SMJERNICE ZA FARMAKOLOŠKO LIJEČENJE ŠEĆERNE BOLESTI TIPA 2. Liječnički vjesnik, 138 (1-2), 0-0. Preuzeto s https://hrcak.srce.hr/172812
MLA 8th Edition Rahelić, Dario, et al. "HRVATSKE SMJERNICE ZA FARMAKOLOŠKO LIJEČENJE ŠEĆERNE BOLESTI TIPA 2." Liječnički vjesnik, vol. 138, br. 1-2, 2016, str. 0-0. https://hrcak.srce.hr/172812. Citirano 25.11.2020.
Chicago 17th Edition Rahelić, Dario, Velimir Altabas, Miro Bakula, Stjepan Balić, Ines Balint, Biserka Bergman Marković, Nenad Bičanić, et al. "HRVATSKE SMJERNICE ZA FARMAKOLOŠKO LIJEČENJE ŠEĆERNE BOLESTI TIPA 2." Liječnički vjesnik 138, br. 1-2 (2016): 0-0. https://hrcak.srce.hr/172812
Harvard Rahelić, D., et al. (2016). 'HRVATSKE SMJERNICE ZA FARMAKOLOŠKO LIJEČENJE ŠEĆERNE BOLESTI TIPA 2', Liječnički vjesnik, 138(1-2), str. 0-0. Preuzeto s: https://hrcak.srce.hr/172812 (Datum pristupa: 25.11.2020.)
Vancouver Rahelić D, Altabas V, Bakula M, Balić S, Balint I, Bergman Marković B i sur. HRVATSKE SMJERNICE ZA FARMAKOLOŠKO LIJEČENJE ŠEĆERNE BOLESTI TIPA 2. Liječnički vjesnik [Internet]. 2016 [pristupljeno 25.11.2020.];138(1-2):0-0. Dostupno na: https://hrcak.srce.hr/172812
IEEE D. Rahelić, et al., "HRVATSKE SMJERNICE ZA FARMAKOLOŠKO LIJEČENJE ŠEĆERNE BOLESTI TIPA 2", Liječnički vjesnik, vol.138, br. 1-2, str. 0-0, 2016. [Online]. Dostupno na: https://hrcak.srce.hr/172812. [Citirano: 25.11.2020.]
Sažetak Introduction: The Croatian Association for Diabetes and Metabolic Disorders of the Croatian Medical Association has issued in 2011 the first national guidelines for the nutrition, education, self-control, and pharmacotherapy of diabetes type 2. According to the increased number of available medicines and new evidence related to the effectiveness and safety of medicines already involved in the therapy there was a need for update of the existing guidelines for the pharmacotherapy of type 2 diabetes in the Republic of Croatia. Participants: as co-authors of the Guidelines there are listed all members of the Croatian Association for Diabetes and Metabolic Diseases, as well as other representatives of professional societies within the Croatian Medical Association, who have contributed with comments and suggestions to the development of the Guidelines. Evidence: These guidelines are evidence-based, according to the GRADE system (eng. Grading of Recommendations, Assessment, Development and Evaluation), which describes the level of evidence and strength of recommendations. Conclusions: An individual patient approach based on physiological principles in blood glucose control is essential for diabetes’ patients management. Glycemic targets and selection of the pharmacological agents should be tailored to the patient, taking into account the age, duration of disease, life expectancy, risk of hypoglycemia, comorbidities, developed vascular and other complications as well as other factors. Because of all this, is of national interest to have a practical, rational and applicable guidelines for the pharmacotherapy of type 2 diabetes.